



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/146073/>

Version: Accepted Version

Article:

Letsinger, S, Kay, P, Rodríguez-Mozaz, S et al. (2019) Spatial and temporal occurrence of pharmaceuticals in UK estuaries. *Science of the Total Environment*, 678. pp. 74-84. ISSN: 0048-9697

<https://doi.org/10.1016/j.scitotenv.2019.04.182>

Crown Copyright © 2019 Published by Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
<http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Spatial and temporal occurrence of pharmaceuticals in UK estuaries

Sarah Letsinger¹, Paul Kay^{1*}, Sara Rodríguez-Mozaz², Marta Villagrassa², Damià Barceló²

Jeanette M. Rotchell³

*Corresponding author p.kay@leeds.ac.uk

¹ School of Geography, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT

² Catalan Institute for Water Research (ICRA), H₂O Building, Scientific and Technological Park of the University of Girona, Emili Grahit 101, E-17003, Girona, Spain

³ School of Environmental Sciences, University of Hull, Cottingham Road, Hull, HU6, 7RX

Abstract

There is a lack of data on the occurrence of pharmaceuticals in estuaries worldwide, with little understanding of their temporal and spatial variations globally. Ibuprofen, paracetamol, diclofenac, trimethoprim and citalopram were measured in twelve estuaries in the UK. Initially, these compounds were monitored in the Humber Estuary, where samples were taken every two months over a twelve month period in order to assess their spatial and temporal variations. Ibuprofen was found at some of the highest concentrations ever measured in an estuary globally (18 – 6297 ng l⁻¹), with paracetamol also measured at relatively high concentrations (4 – 917 ng l⁻¹) in comparison to the other compounds. In terms of spatial distribution, a pattern was observed where the highest concentrations were found at a site at which wastewater is discharged, whilst compound concentrations were often lower upstream and downstream of this site. The downstream profile of pharmaceuticals differed temporally with concentrations highest downstream when input from wastewater effluent was highest. Eleven further estuaries were sampled around the UK in order to put the occurrence of pharmaceuticals in the Humber Estuary into a wider context. Pharmaceutical concentrations in the other estuaries sampled were less than 210 ng l⁻¹ but, again, ibuprofen and paracetamol were found at concentrations higher than other compounds, whereas diclofenac and citalopram were absent in many estuaries. The

Humber, which is the receiving environment for the sewage effluent of approximately 20% (13.6 million people) of the population of England, was observed to have the highest overall concentration of pharmaceuticals in contrast to the other estuaries sampled, thereby representing a worst case scenario for pharmaceutical pollution.

Keywords: Pharmaceuticals; Emerging Contaminants; Estuary; Occurrence; Temporal Distribution; Spatial Distribution

1. Introduction

Despite the extensive and long-term use of pharmaceuticals, it has only been in the past few decades that interest in pharmaceutical pollution has gained popularity and now hundreds of pharmaceuticals have been detected in the aquatic environment (Hughes et al. 2013; Gaw et al. 2014). Their presence is sustained through continuous input from wastewater treatment plants (WWTPs), as well as from improper disposal, agriculture and aquaculture (Godoy et al. 2015). Pharmaceuticals are designed to be biologically active, often at low levels, and their presence in surface water has led to concern over their potential biological effect (Santos et al. 2010). Many pharmaceuticals (e.g. diclofenac and fluoxetine) have been found to illicit a negative response on biota in laboratory exposures at concentrations similar to those found in the aquatic environment (Eades and Waring 2010; Franzellitti et al. 2013; Minguéz et al. 2016).

The fate of pharmaceuticals is best understood in the freshwater environment, with input, environmental conditions, biological degradation and sediment-related processes playing a prominent role in their spatial and temporal distribution (Li 2014). Pharmaceuticals often show a decline in concentration downstream from input sources as the result of dilution, degradation and partitioning to sediment (Kunkel and Radke 2012). However, due to the prevalence of WWTPs, this leads to the continuous input of pharmaceuticals into the environment. As a result, these processes are not enough to sufficiently remove compounds leading to their high detection in the aquatic environment and, potentially, transportation into estuaries and coastal waters (Ebele et al. 2017).

Estuaries are receiving waters, often for many rivers, acting as a confluence for contaminants and therefore increasing the potential risk of pharmaceutical pollution in these environments (Ridgway and Shimmield 2002). Estuaries are ecologically important to ecosystem services, providing habitat for many species and acting as an area for recreation and transport (Ridgway and Shimmield 2002). Despite this, few studies have measured the occurrence of pharmaceuticals in estuaries, and those that do exist typically lack the resolution to determine spatial and temporal patterns (Table 1). Studies which have investigated the spatial and temporal patterns of pharmaceuticals are often locally focused, monitoring only one estuary (for example Tamtam et al., 2012; Hedgespeth et al. 2012; Cantwell et al. 2017), and it is important to determine if any patterns seen are relevant at a wider scale and represent a risk to the environment.

This study aimed to further contribute to the overall picture of pharmaceutical contamination in estuaries. Five target compounds, ibuprofen, paracetamol, diclofenac, trimethoprim and citalopram, were chosen for the present study, based on their prevalent usage and predicted risk to the aquatic environment (National Health Service 2017; Roos et al. 2012). To the authors' knowledge, citalopram has not previously been monitored in the estuarine environment (Table 1). Moreover, monitoring of the aforementioned compounds is limited, with some of these measurements dating back almost fifteen years. The target compounds were measured every other month over a twelve month period at various sites in the Humber Estuary to determine their spatial and temporal occurrence. In addition, eleven further estuaries, located in other parts of the UK, were selected in order to determine whether concentrations observed in the Humber were representative of other estuaries.

78 **Table 1:** Maximum concentrations of ibuprofen, paracetamol, diclofenac and trimethoprim detected in
79 estuaries globally (ng l⁻¹). Citalopram has not previously been monitored in any estuaries.

Region	Estuary	Ibuprofen	Paracetamol	Diclofenac	Trimethoprim	Reference
Asia	Jiulong, China	21	13	11		Sun et al. (2016)
	Hailing Bay, China				37	Chen et al. (2015)
	Qinzhou Bay, China			7		Cui et al. (2019)
	Yangtze, China			<MDL		Yang et al. (2011)
	Yangtze, China				330	Zhang et al. (2012)
	Yangtze, China		<MDL			Zhao et al. (2015)
Europe	Seine, France				45	Tamtam et al. (2008)
	Elbe, Germany	1		1		Weigel et al. (2002)
	Arade, Portugal	28	88	31		Gonzalez-Rey et al. (2015)
	Douro, Portugal				16	Madureira et al. (2010)
	Tejo, Portugal	<MDL	11	52	8	Reis-Santos et al. (2016)
	Bilbao, Spain		440	650	2046	Mijangos et al. (2018)
	Plentzia, Spain		49	22	6	Mijangos et al. (2018)
	Urdaibai, Spain		321	35	3	Mijangos et al. (2018)
	Belfast Lough, UK	376	<MDL	<MDL	32	Thomas and Hilton (2004)
	Mersey, UK	386	<MDL	195	569	Thomas and Hilton (2004)
	Tees, UK	88	<MDL	191	17	Thomas and Hilton (2004)
	Thames, UK	928	<MDL	125	<MDL	Thomas and Hilton (2004)
	Thames, UK				19	Munro et al. (2019)
	Tyne, UK	755		90	46	Thomas and Hilton (2004)
North America	Charleston Harbour, USA	8	28			Hedgespeth et al. (2012)
America	Jamaica Bay, USA	38	156		125	Benotti and Brownawell (2007)
	Narragansett Bay, USA		60		18	Cantwell et al. (2017)

	New York Bay, USA	162	14	Cantwell et al. (2018)
	San Francisco, USA		4	Klosterhaus et al. (2013)
Oceania	Sydney, Australia	31		Birch et al. (2015)

80

81 2. Methods

82 2.1 Study Area

83 The Humber Estuary is a macrotidal estuary located in Yorkshire, on the East Coast of
84 England, UK (Figure 1). It is 303 km², has an average depth of 6.5 m and is the confluence
85 of the Rivers Ouse, Trent and Hull which pass through some of the largest urban areas in
86 the UK, thus it is the receiving water for approximately 20% of UK effluent (European
87 Environment Agency, 2019; Table 2). Samples were collected from nine sites along a 65 km
88 stretch on the North side of the estuary (Figure 1). Two of these were located in the River
89 Ouse; A1 was the furthest upstream and A2 was located less than 1km upstream from the
90 confluence with the Humber Estuary. The furthest site upstream in the Humber Estuary (R1)
91 was the receiving site for effluent from Melton WWTP, which serves a population equivalent
92 (PE) of 12,255 (European Environment Agency, 2017). Three sites (R2-R4) were positioned
93 every 2 km downstream from R1. Three final sites (A3-A5) were located 20km from R1 in the
94 lower estuary and 15 km from the mouth. Further information on site location can be found in
95 supplementary material S1. The Humber Estuary is an important site for conservation and
96 has been designated as a Special Protection Area (SPA), also containing a Special Area of
97 Conservation (SAC). It is also a vital habitat for many species of international importance,
98 providing habitat for 4.1% of the red knot (*Calidris canutus*) and 5.7% of the common
99 redshank (*Tringa tetanus*) international populations, and as a result has also been
100 designated as a RAMSAR site (Buck et al. 1997)

101 Samples were also collected from eleven further estuaries which encompassed a range of
102 estuary types, tidal ranges and sizes (Table 2). The total PE was calculated for the WWTPs

in the catchment area of each estuary (Table 2); further information on the proximity of WWTPs to the sampling sites in each estuary can be found in supplementary material S2. Many of these estuaries have been designated as SACs, SPAs and RAMSAR sites as the result of the sensitive and important species resident to them.

Table 2: Information on the type and size of estuaries sampled (Davidson et al.1991). Information on the number of WWTPs and the population equivalent served in 2014 was calculated from an interactive wastewater treatment map (European Environment Agency 2019).

Estuary	Type	Estuary Area (km ²)	Tidal Type	Number of WWTPs in Catchment	Total PE (000s)
Cromarty	Complex	92.3	Mesotidal	3	15.6
Forth	Complex	84.0	Macrotidal	33	1 613.3
Humber	Coastal Plain	303.6	Macrotidal	304	13 674.7
Mersey	Coastal Plain	89.1	Macrotidal	30	3 689.7
Portsmouth	Ria	15.9	Macrotidal	2	383
Severn	Coastal Plain	556.8	Macrotidal	171	6 724.4
Solway	Complex	420.6	Macrotidal	20	314.9
Tay	Complex	121.3	Mesotidal	12	167.6
Tees	Coastal Plain	13.5	Macrotidal	9	844.9
Thames	Coastal Plain	46.5	Macrotidal	198	16 510.5
Tyne	Complex	7.9	Macrotidal	6	1 092.8
Ythan	Barbuilt	2.8	Mesotidal	1	11.2

2.2 Sampling

2.2.1 Seasonal Monitoring

Sampling was carried out in the Humber Estuary, UK, every two months from October 2016 to August 2017 at sites R1-R4 (Figure 1). Samples were also collected from four additional sites (A1-A2 and A4-A5) in October, February and June, and a further site (A3) in February and June (Figure 1). Sampling was carried out during a high neap tide (± 3 hours) to minimise differences in diurnal concentrations as the result of tides (Lara-Martin et al. 2014). At each site, 3 x 1 L of surface seawater were collected in amber glass bottles and temperature, pH and dissolved oxygen determined using a HACH meter and salinity (0 – 27 ppt) measured with a refractometer (supplementary material S1). Water samples were kept on ice or in the fridge at 4 °C and extracted within 48 hours for analysis of pharmaceuticals.

2.2.2 UK Wide Monitoring

Sampling was carried out in August and September 2017 during high tides (± 3 hours) in eleven additional UK estuaries in order to provide a wider context for the concentrations of pharmaceuticals seen in the Humber Estuary (Figure 1). Within each estuary, sites were chosen in the upper, middle and lower parts of the estuary and 1 L of water was collected at each of these in amber glass bottles. Temperature, pH, dissolved oxygen and salinity (0-34 ppt) were determined as above and samples stored and extracted in the same manner (supplementary material S2).




Figure 1 Map of field sites for seasonal and UK wide monitoring of selected pharmaceuticals. The sites in the box (R1-R4) indicate those which were sampled every two months whilst A1-A2 and A3-A5 were sampled every four months.

2.3 Chemical Analysis

2.3.1 Study Compounds

Five study compounds, ibuprofen, paracetamol, diclofenac, trimethoprim and citalopram, were chosen for monitoring (Table 3) and standards of diclofenac sodium (≥ 98.5), acetaminophen ($\geq 99\%$), citalopram (≥ 98), ibuprofen ($\geq 98\%$), and trimethoprim ($\geq 98\%$) were supplied by Sigma-Aldrich Ltd. (Dorset, UK).

Table 3: Physico-chemical characteristics of the study compounds. Physico-chemical data obtained from Alygizakis et al. (2016), Bayen et al. (2013) and Kasprzyk-Hordern et al. (2007). Prescription data obtained from National Health Service (2019); supplementary material S3.

Compound	Therapeutic Use	Prescriptions (kg year ⁻¹)	Water Solubility (mg l ⁻¹)	Log _{KOW}	Molecular Weight	pKa
Ibuprofen	Nonsteroidal anti-inflammatory drug (NSAID)	82,756	41.05	3.97	206.29	9
Paracetamol	Painkiller	2,169,244	22.7	0.9	151.16	9.9
Diclofenac	NSAID	5459	4.52	4.51	296.15	4.2
Trimethoprim	Antibiotic	8444	171.1	1.4	290.32	7.1
Citalopram	Antidepressant	9204	4.02	3.74	324.39	9.4

2.3.2 Solid Phase Extraction

A composite sample was made by combining the 3 x 1L surface water samples collected from each site during seasonal monitoring, or from each of the estuaries during the UK-wide survey, by adding them together in a 5 L beaker and stirring vigorously for two minutes. A 500 mL sub-sample was filtered through a 0.45 µm cellulose filter (Scientific Laboratory Supplies, Hesse, UK) under vacuum. Solid phase extraction was performed on the filtered water samples using Oasis HLB cartridges (Waters Corporation, Massachusetts, USA), which were conditioned with 5 mL 100% methanol followed by 5 mL deionised water at a rate of 1 mL min⁻¹. The sample was loaded on to the cartridge at a rate of 10 mL min⁻¹, during which care was taken not to let the sorbent material dry out. The cartridges were then

rinsed with 5 mL deionised water and the sorbent was dried under vacuum for 15 minutes to remove excess water prior to elution. Elution was performed with 2 x 5 mL 0.1% trifluoroacetic acid in methanol. The eluent was evaporated to dryness using a rotary evaporator (40°C, speed 7) and reconstituted with methanol: water (10:90).

SPE recovery was evaluated by spiking known concentrations (100, 200, and 1000 ng l⁻¹) of all study compounds into three replicates each of artificial seawater made up to 20 ppt in deionised water (supplementary material S4). The mean recovery across all concentrations was used to correct the measured environmental concentrations (Table 4).

Table 4: Mean method detection limits ($\pm$ standard deviation), mean method quantification levels ($\pm$ standard deviation) and mean recovery ($\pm$ standard deviation) of target compounds.

Compound	MDL (ng l ⁻¹)	MQL (ng l ⁻¹)	Recovery (%)
Citalopram	0.34 (0.25)	1.18 (0.85)	43 (5.5)
Diclofenac	1.77 (1.35)	5.91 (4.49)	20 (11.0)
Ibuprofen	1.45 (0.41)	4.83 (1.38)	73 (34.0)
Paracetamol	3.28 (1.82)	10.93 (6.07)	86 (34.1)
Trimethoprim	0.07 (0.04)	0.24 (0.12)	63 (10.6)

2.3.3 UltraperformanceTM-ESI-(QqLIT) MS/MS analysis

Analysis was carried out according to Gros et al. (2012). Briefly, chromatographic separations were performed with a Waters Acquity Ultra-Performance liquid chromatograph system equipped with two binary pump systems (Milford, Massachusetts, USA) and coupled to a 5500 QTRAP hybrid quadrupole-linear ion trap mass spectrometer with a turbo ion spray source (Applied Biosystems, Foster Systems, Foster City, CA, USA). Citalopram and trimethoprim were analysed under positive electrospray ionisation (PI) using an Acquity HSS T₃ column (50 mm x 2.1 mm, 1.8µm particle size) and ibuprofen, paracetamol and diclofenac were analysed under negative ion (NI) electrospray using an Acquity BEH C₁₈ column (5 mm x 2.1 mm, 1.7 µm particle size), both from Waters Corporation.

All data acquisition was performed in Analyst 2.1 software. Quantification of analytes was performed by selective reaction monitoring (SRM), monitoring two transitions for each compound as described in Gros et al. (2012). Method detection limits (MDL) and quantification levels (MQL) were determined for each of the compounds based on a signal-to-noise ratio of 3 and 10 respectively (Table 4).

2.4 Statistical Analysis

Statistical analysis was performed in R 3.3.1. In order to determine if there was a difference in the occurrence of pharmaceuticals between sampling months, concentrations from R1-4 were grouped together, as these sites were sampled during all of the sampling periods. A Friedman's Test followed by a Nemenyi post-hoc test were conducted using the PMCMR package (Pohlert 2014). All data is presented in graphs created by the ggplot2 package (Wickham 2016).

3. Results

3.1 Humber Estuary

Pharmaceuticals were frequently detected (58 - 97% of samples for individual study compounds) in the Humber Estuary (Table 5) and concentrations followed the order of ibuprofen>paracetamol>diclofenac>trimethoprim>citalopram. Whilst mean concentrations were in the order of 100 ng l⁻¹ or below, maximum concentrations were approximately five to ten times higher (Table 5; supplementary material S5). Maximum levels of ibuprofen and paracetamol detected in the Humber are the highest concentrations reported in estuaries to date (Table 1).

Table 5: Pharmaceutical concentrations (ng l⁻¹) in the Humber Estuary (n=38) during a 12 month sampling campaign. Values were corrected based on mean recovery values (Table 3). Max = maximum concentration, SD = standard deviation. Detection rate is the amount of samples above the method quantification limit (MQL).

Compound	Detection Rate (%)	Max (ng l ⁻¹)	Mean (ng l ⁻¹)	SD
Ibuprofen	97.37	6297.14	665.58	1481.49
Paracetamol	73.68	916.88	88.65	163.66
Diclofenac	57.89	250.8	51.44	68.29
Trimethoprim	92.11	247.02	27.43	54.56
Citalopram	89.47	42.93	6.39	7.66

A general pattern was observed in the occurrence of pharmaceuticals in the Humber with concentrations peaking at sampling site R1 (Figures 2) and those up (samplings sites A1-A2) and downstream (sampling sites R2-A5) of this site similar to each other. However, this pattern was not entirely consistent and sometimes concentrations declined downstream (A3-A5). Maximum concentrations were generally seen at sampling site R1 although during some of the sampling periods they occurred at sites R2-R4.

Of the three months where all sites were sampled February had the highest detection rates and concentrations of pharmaceuticals at downstream sites (A3-A5), whilst many of the compounds were absent at these sites in October and June (Figure 2). In contrast, ibuprofen was an exception to this with concentrations found at these sites during all of the sampling periods. Citalopram also showed little decline in downstream concentrations in June and was present at A3-A5 at concentrations similar to or higher than many of the sites further upstream (Figure 2). There appeared to be a relationship between the concentration of pharmaceuticals at R1 and those seen at the other sites; typically, a higher concentration at R1 resulted in a higher presence at sites further downstream (Figure 2).

221 Trimethoprim was the only compound to show a statistically significant difference between
222 sampling months (Friedman's Test, chi-squared = 14.71, $p < 0.05$) with concentrations
223 significantly higher in winter (December and February; 3.29 – 166.54 ng l⁻¹) compared to
224 October and the summer months (June and August; 0 – 142 ng l⁻¹; Figure 3). Nevertheless,
225 the difference was almost significant for ibuprofen ($p = 0.054$) and citalopram ($p = 0.051$).
226 For citalopram, February had the highest concentrations (3.74 – 42.93 ng l⁻¹), whereas
227 ibuprofen concentrations were higher in April and June (186.37 – 6297.14 ng l⁻¹; Figures 3)
228 in comparison to the other sampling periods. All compounds were found at their lowest mean
229 concentrations in August (Figures 3), with no peaks seen at sampling site R1 (Figure 2).




Figure 2 Concentrations of target analytes at nine sites in the Humber Estuary. Values were corrected based on mean recovery values (Table 3). Sites are listed from furthest upstream (A1) to furthest downstream (A5). R1-R4 were sampled every sampling event whilst the other sites were only sampled in October, February and June, except for A1 which was not sampled in October.




Figure 3 Mean bi-monthly concentrations ($\pm$ one standard deviation) of (A) Ibuprofen (B) Paracetamol (C) Diclofenac (D) Trimethoprim and (E) Citalopram at the four sites monitored most frequently (R1-R4). Values were corrected based on mean recovery values (Table 3). Letters denote statistically significant difference (Friedman's Test).

3.2 UK-wide sampling

Pharmaceuticals were detected in all of the estuaries sampled around the UK but only at concentrations in the low ng l⁻¹ range, generally lower than those detected in the Humber Estuary (Figure 4). Relative concentrations were similar to that found in the Humber;

ibuprofen>paracetamol>diclofenac>citalopram>trimethoprim (supplementary material S6). Ibuprofen and trimethoprim were present in all of the estuaries sampled whereas diclofenac was only detected in two of the other estuaries, the Cromarty and Thames (Figure 4). The Thames and Humber were the only estuaries to contain all of the compounds. The Humber had the overall highest concentration of pharmaceuticals and only the Cromarty and Tay had a total concentration of pharmaceuticals over 200 ng l⁻¹ (Figure 4).




Figure 4 Concentrations of citalopram, diclofenac, ibuprofen, paracetamol and trimethoprim across eleven estuaries in the UK. Concentrations have been corrected for recovery (Table 3). Concentrations reported for the Humber are maximum concentrations measured in August, when the wider UK survey was undertaken.

4. Discussion

Most monitoring studies to date have been carried out in freshwater systems as it was originally thought that estuaries and coastal waters would dilute compounds so that they would be undetectable (Fabbri and Franzellitti 2016). Despite this hypothesis,

pharmaceutical contamination was found to be widespread and all of the estuaries monitored in the current study contained at least three of the target analytes at levels of a similar magnitude to those found in the freshwater environment, and higher than those measured in many other estuaries (Hughes et al. 2013; Table 1). The levels of pharmaceuticals detected in this study contribute to the overall picture on pharmaceutical pollution and add to the growing evidence of this global issue (aus der Beek et al. 2016). Our work indicates that the limited monitoring carried out to date may not have captured peak concentrations that occur in these environments and clearly highlights that further work is needed.

Ibuprofen was detected at the highest concentrations and in all of the estuaries sampled, with its occurrence not only exceeding levels detected in other estuaries (Table 1) but also those seen in river water both in the UK (Barbara Kasprzyk-Hordern et al. 2008; Kay et al. 2017; Burns et al. 2017, 2018) and globally (Hughes et al. 2013). Ibuprofen has only been measured in seven estuaries previously, with maximum concentrations all under 1000 ng l⁻¹ (Table 1). Further monitoring studies should include ibuprofen as a priority to determine if high concentrations seen in the UK are similar to those elsewhere.

Concentrations of paracetamol, diclofenac and trimethoprim were similar to those seen in other global estuaries, with mean concentrations less than 100 ng l⁻¹ (Table 1). Whilst maximum concentrations of paracetamol were similar to those detected in rivers (Barbara Kasprzyk-Hordern et al. 2008; Burns et al. 2017), concentrations of diclofenac and trimethoprim were considerably lower (Hughes et al. 2013; Nakada et al. 2017). In the present study, water samples were collected at high tide, when concentrations would be expected to be lowest, so it is possible that these levels could be higher at other points in the tidal cycle (Yang et al. 2016). This is the first study to measure the occurrence of citalopram although concentrations were low and did not exceed 50 ng l⁻¹, in agreement with previous studies which have monitored citalopram in rivers (Hughes et al. 2013). Nevertheless, PNECs for citalopram are below this level (Minguez et al. 2016).

Whilst widespread occurrence of pharmaceuticals was seen in the UK patterns in their spatial and temporal distributions within and between estuaries were observed.

4.1 Humber Estuary

4.1.1 Spatial Variation

It is generally expected that pharmaceutical concentrations will decrease downstream due to physical processes in an estuary leading to their breakdown and removal (Daughton 2016). The spatial pattern of pharmaceutical occurrence in the Humber Estuary followed this pattern to a degree; peak concentrations were found in the middle of the estuary, particularly at R1, where samples were collected next to an outlet from a wastewater treatment plant (WWTP), indicating that WWTPs could be a significant source of pharmaceuticals in the Humber Estuary. Input from WWTPs has been attributed as the largest source of pharmaceutical pollution in the aquatic environment (Caldwell 2016). In some cases maximum concentrations were detected outside of this site; in April and June maximum concentrations for paracetamol and ibuprofen occurred at sites R2-4. It is difficult to determine what caused these peaks although these sites are within 6km from R1, so it is possible that the large increases seen at these sites are still due to input at R1, and fluctuations between these sites are the result of sampling timing (Ort et al. 2010). The site (R4) which showed the highest levels ($6.2 \mu\text{g l}^{-1}$) of ibuprofen was also 7km upstream from the confluence of the River Hull. Transport of pharmaceuticals from this tributary upstream during high tide could also account for the increases seen. The River Trent, located near the confluence with the Ouse (Figure 1), could also account for the addition of further pharmaceuticals. Inputs of pharmaceuticals in other studies have also been attributed to other sources such as improper disposal, leaching from landfills or through veterinary usage and subsequent runoff of these compounds into the aquatic environment, which could also account for these differences (Bound and Voulvoulis 2005; Ebele et al. 2017).

Dilution plays a key role in the fate of pharmaceuticals in the aquatic environment and the decrease in concentrations after R1 is presumably caused by dilution away from the input source (Baker and Kasprzyk-Hordern 2013). Decline of pharmaceutical concentrations downstream in the estuary was observed to a greater extent for some compounds and, therefore, is unlikely to be entirely due to dilution. Degradation has been found to be a significant factor affecting the fate of pharmaceuticals and could account for these differences (Caracciolo et al. 2015). Citalopram experienced the lowest decrease in concentration downstream and was typically found at the same concentration or higher at A5 compared to A1, which could be explained by the low degradation which has been observed in other studies (Metcalf et al. 2010; Styris have et al. 2011). Ibuprofen, paracetamol and trimethoprim also showed little decline in concentration beyond initial dilution after R1, which is consistent with what has been seen at other sites. These compounds have been found up to 10 km downstream from a WWTP (Bendz et al. 2005, Kay et al. 2017, Burns et al. 2018), and trimethoprim has even been found 200 km downstream from a WWTP (Tamtam et al. 2008). Further WWTPs are located within the estuary (European Environment Agency, 2019) which could also account for this lack in decline. Diclofenac on the other hand, was not detected at A3 or A5 during any of the sampling periods, but was found at A4. The downstream decline of diclofenac has been found to be variable, with some studies finding it to be more persistent than others (Bendz et al. 2005; Wilkinson et al. 2017). Removal of compounds through degradation and sorption to sediment has been found to be highly dependent on environmental conditions and sediment type.

4.2.1 Temporal Variation

Seasonal differences of pharmaceuticals have been observed in a number of studies and these are often attributed to changes in usage and local environmental conditions (Golovko et al. 2014b; Moreno-González et al. 2014). Trimethoprim was the only compound to show significant temporal differences in concentrations (at sites R1-R4), with average winter concentrations more than double that of those found during the summer months. Previous

studies have explained the occurrence of antibiotics in winter due to their higher usage in those months to treat seasonal infections (Verlicchi and Zambello 2016). The temporal differences seen in the occurrence of trimethoprim in the Humber Estuary appeared to follow this pattern as prescriptions were highest in October 2016 to March 2017 and lowest in August 2017 (supplementary material S4). Trimethoprim has been observed to have higher winter concentrations in some studies (Golovko et al. 2014b) but not in others (Burns et al. 2018). Burns et al. (2018) found higher levels of trimethoprim during spring in the Ouse (upstream from A1), which was attributed to hydrological differences seen between the seasons sampled. As a result, it is likely that the temporal differences in trimethoprim are the result of different site specific conditions or daily variations. Temporal variations in other studies have also been explained by lower temperatures leading to lower degradation (Golovko et al. 2014a), however, input at R1 was highest in April. The other target compounds have exhibited seasonal patterns in other studies but did not in the Humber. Paracetamol, for instance, has been detected at high concentrations in spring in some rivers but winter in others, whilst other studies found no temporal variations (Paíga et al. 2016; Ma et al. 2017; Burns et al. 2018).

Temporal variations in the downstream pattern of pharmaceuticals were also observed, with the greatest variation seen at the sites furthest downstream (A3-A5). Pharmaceuticals were mostly absent from these sites in October, with the exception of ibuprofen, where concentrations were reduced. Sampling at high tide could account for the absence of these pharmaceuticals downstream as the result of increased dilution or transport of contaminants upstream (Munro et al. 2019). Pharmaceutical concentrations often fluctuate diurnally as the result of the timing of effluent discharges from WWTPs and combined sewer overflows (CSOs), as well as variations in wastewater quantities as the result of consumption patterns (Xu et al. 2007). To an extent, there was a pattern in the presence of compounds at R1 consistent with those seen downstream in the estuary, so it is possible that the temporal variations could be the result of these daily variations, instead of conditions seen seasonally.

The concentration of pharmaceuticals at R1 were lowest in October and the low input could, in part, account for the absence of compounds seen at sites furthest downstream (A3-A5). Likewise, concentrations for the majority of compounds were highest at R1 during February where concentrations were highest at sites furthest downstream (A3-A5). This is further evidence that there is a difference in input from WWTPs. R1 is not the only site at which wastewater is discharged but if these other sites exhibit the same temporal variations then it could explain the differences observed in concentrations at A3-A5. WWTP removal has been found to be less efficient during the winter time due to lower temperatures and decreased biodegradation, leading to higher concentrations in effluent (Vieno et al. 2005). At R1, concentrations for all compounds were lowest in August when temperatures were warmest (supplementary material S1).

4.3 UK Estuaries

The Humber Estuary was shown to represent a worst case scenario in terms of pharmaceutical pollution, with all five pharmaceuticals present at relatively high concentrations. Of the estuaries sampled, it was the second highest impacted by WWTPs, with a PE of approximately 13.7 million people. The Thames, which was the most impacted, was the only other estuary to contain all five compounds. A higher presence of pharmaceuticals is frequently seen in large urban areas due to their increased usage (Hong et al. 2018). With the exception of both the Humber and the Thames estuaries, there was no apparent relationship between the number of WWTP and concentrations (Table 2). The Cromarty Firth, which was the receiving water of only 3 WWTPs (15,600 PE), exhibited similar levels of pharmaceuticals to the Humber. This could be explained by differences in WWTP efficiency, as technology used in WWTPs can greatly affect the removal of pharmaceuticals. For example, ibuprofen removal has been reported to be between 7% and 99% at different WWTPs (Radjenovic et al. 2007; Jelic et al. 2015). It is possible that the removal efficiency of WWTPs could differ between areas, with rural areas being less efficient

as they are serving smaller populations. Rural areas are more likely to have a higher occurrence of septic tanks, which could contribute to the elevated levels seen in the Cromarty (Hanamoto et al. 2018). Whilst the Humber experienced the lowest concentration in August, it is possible that seasonal variations in population in areas like the Scottish Highlands (a tourist destination), where the Cromarty is located, could be responsible for these higher concentrations, increasing pressure on WWTPs. Pharmaceuticals in a Portuguese river have previously shown higher concentrations which was thought to be the result of increased summer populations (Rocha et al. 2014).

The presence of pharmaceuticals is greatly influenced by environmental conditions and proximity of the sampling site to input sources, possibly accounting for some of the apparent differences in concentrations observed between estuaries. Water samples from different locations in the estuary were mixed together and a subsample was taken to obtain a snapshot of the presence of pharmaceuticals, and it is likely that these concentrations will vary depending on these factors. This could possibly explain the absence of diclofenac, which in the Humber study was frequently undetected in sites downstream in the estuary. Citalopram also had a low detection (50%) in estuaries, however, it was detected in estuaries which have the highest PE.

There are also likely to be more complex interactions in play which further affect the occurrence of pharmaceuticals in estuaries and which can help to explain the spatial differences seen. Differences in site specific conditions such as salinity profiles and hydrology can affect sorption processes, degradation and dilution. Undoubtedly, these processes, in conjunction with daily variations in rainfall and temperature, are likely to be responsible for differences in concentrations in estuaries between sampling periods, yet it is still clear that pharmaceutical pollution is a ubiquitous problem in estuaries (Tamtam et al. 2008).

Ibuprofen, paracetamol, diclofenac and trimethoprim were previously monitored in the Mersey, Thames, Tees and Tyne estuaries (as well as Belfast Lough) in 2002 (Thomas and

Hilton, 2004). It was also found that ibuprofen was present at the highest concentrations. Paracetamol, however, was not detected in any of the estuaries sampled in 2002, which indicates that the occurrence of this compound could be rising. A rise in pharmaceuticals would be consistent with what has been found in other areas. For example, analysis of sediment cores in Jamaica showed an overall rise in pharmaceutical concentrations over time, with these concentrations doubling over the last decade (Lara-Martin et al. 2015). This highlights the importance of establishing baseline measurements of pharmaceuticals, in order to determine areas most at risk and therefore requiring continued monitoring. The Humber Estuary likely poses the greatest risk, particularly due to the high level concentrations of ibuprofen. Other large urban estuaries (such as the Thames and Severn) may also warrant a further detailed study. However, as seen with the Cromarty, focus on monitoring should be extended to rural areas as well.

5. Conclusion

All five target analytes, ibuprofen, paracetamol, diclofenac, trimethoprim and citalopram, were detected in twelve estuaries in the UK. Diclofenac is a compound that has been highlighted by EU legislation as a potential concern yet paracetamol and ibuprofen were consistently detected at higher concentrations and at levels which could be toxic to aquatic organisms (Vestel et al. 2016). In particular, the concentrations of ibuprofen measured indicate that the limited monitoring of pharmaceuticals in estuaries around the globe to date has not accurately quantified peak concentrations. Whilst trimethoprim was detected in every sample it was only present at concentrations in the low ng l⁻¹ range and although citalopram was present at lowest concentrations it showed the least change in concentration downstream. A more intensive monitoring regime of the Humber Estuary showed that pharmaceutical input from WWTPs is a significant source and could explain the overall higher concentrations of pharmaceuticals in large urban estuaries. Despite this, a rural estuary had the highest concentration of ibuprofen which may be due to lower removal at

smaller rural sewage works. More detailed studies need to be undertaken in order to understand the complex interactions taking place in estuaries which could affect the fate of pharmaceuticals.

Whilst there was little significant variation of pharmaceutical concentrations between sampling periods in the Humber Estuary, August typically had the lowest input from WWTPs and overall lowest concentrations, which is when samples were taken from estuaries throughout the UK. Consequently, it could be expected that pharmaceutical concentrations may exceed those measured. Additionally, samples were taken on a high tide when it would be expected that concentrations are lowest due to dilution. This study provides an important baseline of pharmaceutical measurements in the UK and highlights ibuprofen as a compound which may warrant further assessment. This work provides further evidence to the growing problem of pharmaceutical pollution, highlighting that it is not only an urban and localised issue.

Acknowledgements

This project was primarily funded via a Natural Environmental Research Council PhD studentship (165232) to S. Letsinger. This work was also supported by water@leeds and by the European Union through the European Development Fund (ERDF) and by the Generalitat de Catalunya (Consolidate Research Group ICRA-ENV 2017 SGR 1124). S. Rodriguez-Mozaz acknowledges the Ramon y Cajal program (RYC-2014-16707)

References

- Alygizakis NA, Gago-Ferrero P, Borova VL, Pavlidou A, Hatzianestis I, Thomaidis NS (2016) Occurrence and spatial distribution of 158 pharmaceuticals, drugs of abuse and related metabolites in offshore seawater. *Sci Total Environ* 541: 1097–1105. doi: 10.1016/j.scitotenv.2015.09.145
- Arpin-Pont L, Bueno MJM, Gomez E, Fenet H (2014) Occurrence of PPCPs in the marine environment: a review. *Environ Sci Pollut Res.* 23(6):4978-91 doi: 10.1007/s11356-014-3617-x
- Aus der Beek T, Weber F, Bergmann A, Hickmann S, Ebert I, Hein A, Kuster A (2016) Pharmaceuticals in the environment - Global occurrences and perspectives. *Environ. Toxicol. Chem.* 35(4): 823-835 doi: 10.1002/etc.3339
- Baker DR, Kasprzyk-Hordern B (2013) Spatial and temporal occurrence of pharmaceuticals and illicit drugs in the aqueous environment and during wastewater treatment: New developments. *Sci Total Environ* 454–455: 442–456. doi: 10.1016/j.scitotenv.2013.03.043
- Bayen S, Zhang H, Desai MM, Ooi SK, Kelly BC (2013) Occurrence and distribution of pharmaceutically active and endocrine disrupting compounds in Singapore's marine environment: Influence of hydrodynamics and physical-chemical properties. *Environ Poll* 182: 1–8. doi: 10.1016/j.envpol.2013.06.028
- Bendz D, Paxéus NA, Ginn TR, Loge FJ (2005) Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Höje River in Sweden. *J Hazard Mat* 122: 195–204. doi: 10.1016/j.jhazmat.2005.03.012
- Benotti MJ, Brownawell BJ (2007) Distriutions of Pharmaceuticals in an Urban Estuary during both Dry and Wet-Weather Conditions. *Environ Sci Technol* 41 (16) 5795-5802 doi: 10.1021/es0629965

501 Birch GF, Drage DS, Thompson K, Eaglesham G, Mueller JF (2015) Emerging contaminants
 502 (pharmaceuticals, personal care products, a food additive and pesticides) in waters of
 503 Sydney estuary, Australia. *Mar Poll Bull* 97(1-2): 56-66

504 Bound JP, Voulvoulis N (2005) Household disposal of pharmaceuticals as a pathway for
 505 aquatic contamination in the United Kingdom. *Environ Health Perspect* 113: 1705–
 506 1711. doi: 10.1289/ehp.8315

507 Buck AL (1997) An inventory of UK estuaries - Volume 5. Eastern England Joint Nature
 508 Conservation Committee, Peterborough

509 Burns EE, Carter LJ, Kolpin DW, Thomas-Oates J, Boxall ABA (2018) Temporal and spatial
 510 variation in pharmaceutical concentrations in an urban river system. *Wat Res* doi:
 511 10.1016/j.watres.2018.02.066

512 Burns EE, Thomas-Oates J, Kolpin DW, Furlong ET, Boxall ABA (2017) Are exposure
 513 predictions, used for the prioritization of pharmaceuticals in the environment, fit for
 514 purpose? *Environ Toxicol Chem* 36: 2823–2832. doi: 10.1002/etc.3842

515 Caldwell DJ (2016) Sources of Pharmaceutical Residues in the Environment and their
 516 Control. *Issues in Environmental Science and Technology* 41: 92–119. doi:
 517 10.1039/9781782622345-00092

518 Cantwell MG, Katz DR, Sullivan JC, Ho Kay, Burgess RM (2017) Temporal and spatial
 519 behaviour of pharmaceuticals in Narragansett Bay, Rhode Island, United States.
 520 *Environ Chem* 36 (7) 1846-1855 doi: 10.1002/etc.3710

521 Cantwell MG, Katz DR, Sullivan JC, Shapley D, Lipscomb J, Epstein J, Juhl AR, Knudson C,
 522 O'Mullan GD (2018) Spatial patterns of pharmaceuticals and wastewater tracers in the
 523 Hudson River Estuary. *Wat Res* 137: 335–343. doi: 10.1016/J.WATRES.2017.12.044

524 Caracciolo AB, Topp E, Grenni P (2015) Pharmaceuticals in the environment:
 525 Biodegradation and effects on natural microbial communities: A review. *J Pharm*

526 Biomed Anal 106: 25–36. doi: 10.1016/j.jpba.2014.11.040

527 Chen H, Liu S, Xu X, Zhou G, Liu S, Yue W, Sun K, Ying G (2015) Antibiotics in the coastal
 528 environment of the Hailing Bay region, South China Sea: spatial distribution, source
 529 analysis and ecological risks. Mar Poll Bull. 95(1) 365-373
 530 doi:10.1016/j.marpolbul.2015.04.025

531 Cui Y, Wang Y, Pan C, Li R, Xue R, Guo J, Zhang R (2019) Spatiotemporal distributions,
 532 source apportionment and potential risks of 15 pharmaceuticals and personal care
 533 products (PPCPs) in Qinzhou Bay, South China. Mar Poll Bull 141: 104-111 doi:
 534 10.1016/J.MARPOLBUL.2019.02.012

535 Davidson NC, Laffoley DD, Doody JP, Way LS, Gordon J, Key R, Pienkowski MW, Mitchell
 536 R, Duff KL (1991) Nature conservation and estuaries in Great Britain. Nature
 537 Conservancy Council, Perborough

538 Daughton CG (2016) Pharmaceuticals and the Environment (PiE): Evolution and impact of
 539 the published literature revealed by bibliometric analysis. Sci Total Environ 562: 391–
 540 426. doi: 10.1016/j.scitotenv.2016.03.109

541 Dong H, Yuan X, Wang W, Qiang Z (2016) Occurrence and removal of antibiotics in
 542 ecological and conventional wastewater treatment processes: A field study. J Environ
 543 Manage 178: 11–19. doi: 10.1016/j.jenvman.2016.04.037

544 Eades C, Waring CP (2010) The effects of diclofenac on the physiology of the green shore
 545 crab *Carcinus maenas*. Mar Environ Res 69: S46–S48. doi:
 546 10.1016/j.marenvres.2009.11.001

547 Ebele AJ, Abou-Elwafa Abdallah M, Harrad S (2017) Pharmaceuticals and personal care
 548 products (PPCPs) in the freshwater aquatic environment. Emerging Contaminants 3: 1–
 549 16. doi: 10.1016/J.EMCON.2016.12.004

550 Environment Agency (2019) Catchment Data Explorer. Available from:

551 <https://environment.data.gov.uk/catchment-planning/> (January 8, 2019).

552 European Environment Agency (2017) Urban Waste Water Treatment Map. Available from:

553 [https://www.eea.europa.eu/themes/water/european-waters/water-use-and-](https://www.eea.europa.eu/themes/water/european-waters/water-use-and-environmental-pressures/uwwtd/interactive-maps/urban-waste-water-treatment-maps)

554 [environmental-pressures/uwwtd/interactive-maps/urban-waste-water-treatment-maps.](https://www.eea.europa.eu/themes/water/european-waters/water-use-and-environmental-pressures/uwwtd/interactive-maps/urban-waste-water-treatment-maps)

555 (March 15, 2019)

556 Fabbri E, Franzellitti S (2016) Human pharmaceuticals in the marine environment: Focus on

557 exposure and biological effects in animal species. *Environ Toxicol Chem* 35: 799–812.

558 doi: 10.1002/etc.3131

559 Franzellitti S, Buratti S, Valbonesi P, Fabbri E (2013) The mode of action (MOA) approach

560 reveals interactive effects of environmental pharmaceuticals on *Mytilus*

561 *galloprovincialis*. *Aquat Toxicol* 140–141: 249–256. doi: 10.1016/j.aquatox.2013.06.005

562 Gaw S, Thomas K V, Hutchinson TH (2014) Sources, impacts and trends of pharmaceuticals

563 in the marine and coastal environment. *Philosoph Trans Royal Soc B* 369. doi:

564 10.1098/rstb.2013.0572

565 Godoy AA, Kummrow F, Pamplin PAZ (2015) Occurrence, ecotoxicological effects and risk

566 assessment of antihypertensive pharmaceutical residues in the aquatic environment - A

567 review. *Chemosphere* 138: 281–291. doi: 10.1016/j.chemosphere.2015.06.024

568 Golovko O, Kumar V, Fedorova G, Randak T, Grabic R (2014a) Removal and seasonal

569 variability of selected analgesics/anti-inflammatory, anti-hypertensive/cardiovascular

570 pharmaceuticals and UV filters in wastewater treatment plant. *Environ Sci Pollut Res*

571 21: 7578-7585 doi:10.1007/s11356-014-2654-9

572 Golovko O, Kumar V, Fedorova G, Randak T, Grabic R (2014b) Seasonal changes in

573 antibiotics, antidepressants/psychiatric drugs, antihistamines and lipid regulators in a

574 wastewater treatment plant. *Chemosphere* 111: 418–426. doi:

575 10.1016/j.chemosphere.2014.03.132

576 Gonzalez-Rey M, Tapie N, Menach KL, Dévier MH, Budzinski H, Bebianno MJ (2015)
577 Occurrence of pharmaceutical compounds and pesticides in aquatic systems. 96(1-2):
578 384-400 doi:10.1016/j.marpolbul.2015.04.029

579 Gros M, Rodríguez-Mozaz S, Barceló D (2012) Fast and comprehensive multi-residue
580 analysis of a broad range of human and veterinary pharmaceuticals and some of their
581 metabolites in surface and treated waters by ultra-high-performance liquid
582 chromatography coupled to quadrupole-linear ion trap tandem. *Jo Chromat A* 1248:
583 104–121. doi: 10.1016/j.chroma.2012.05.084

584 Guo J, Sinclair CJ, Selby K, Boxall ABA (2016) Toxicological and ecotoxicological risk-based
585 prioritization of pharmaceuticals in the natural environment. *Environ Toxicol Chem* 35
586 (6): 1550-1559 doi: 10.1002/etc.3319

587 Hanamoto S, Nakada N, Yamashita N, Tanaka H (2018) Source estimation of
588 pharmaceuticals based on catchment population and in-stream attenuation in Yodo
589 River Watershed, Japan. *Sci Total Environ* 615: 964-971 doi:
590 10.1016/J.SCITOTENV.2017.10.013

591 Hong B, Lin Q, Yu S, Chen Y, Chen Y, Chiang P (2018) Urbanization gradient of selected
592 pharmaceuticals in surface water at a watershed scale. *Sci Total Environ* 634: 448–
593 458. doi: 10.1016/J.SCITOTENV.2018.03.392

594 Hughes SR, Kay P, Brown LE (2013) Global synthesis and critical evaluation of
595 pharmaceutical data sets collected from river systems. *Environ Sci Technol* 47: 661–
596 677. doi: 10.1021/es3030148

597 Jelic A, Rodriguez-Mozaz S, Barceló D, Gutierrez O (2015) Impact of in-sewer
598 transformation on 43 pharmaceuticals in a pressurized sewer under anaerobic
599 conditions. *Wat Res* 68: 98–108. doi: 10.1016/j.watres.2014.09.033

600 Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL (2015) Trends in Prescription

601 Drug Use Among Adults in the United States From 1999-2012. JAMA 314: 1818. doi:
602 10.1001/jama.2015.13766

603 Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ (2007) Multi-residue method for the
604 determination of basic/neutral pharmaceuticals and illicit drugs in surface water by
605 solid-phase extraction and ultra performance liquid chromatography–positive
606 electrospray ionisation tandem mass spectrometry. J Chromat A 1161: 132–145. doi:
607 10.1016/J.CHROMA.2007.05.074

608 Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ (2008) The removal of pharmaceuticals,
609 personal care products, endocrine disruptors and illicit drugs during wastewater
610 treatment and its impact on the quality of receiving waters. Wat Res 42 (13): 3498-3518
611 doi: 10.1016/j.watres.2008.10.047

612 Kay P, Hughes SR, Ault JR, Ashcroft AE, Brown LE (2017) Widespread, routine occurrence
613 of pharmaceuticals in sewage effluent, combined sewer overflows and receiving waters.
614 Environ Poll 220: 1447-1455 doi: 10.1016/j.envpol.2016.10.087

615 Klosterhaus SL, Grace R, Hamilton MC, Yee D (2013) Method validation and
616 reconnaissance of pharmaceuticals, personal care products, and alkylphenols in
617 surface waters, sediments, and mussels in an urban estuary. Environ Int 54: 92-99

618 Kunkel U, Radke M (2012) Fate of pharmaceuticals in rivers: Deriving a benchmark dataset
619 at favorable attenuation conditions. Wat Res. 46(17): 5551-5565 doi:
620 10.1016/J.WATRES.2012.07.033

621 Lara-Martín PA, González-Mazo E, Petrovic M, Barceló B (2014) Occurrence, distribution
622 and partitioning of nonionic surfactants and pharmaceuticals in the urbanized Long
623 Island Sound Estuary (NY). Mar Poll Bull 85: 710-719 doi:
624 10.1016/J.MARPOLBUL.2014.01.022

625 Lara-Martín PA, Renfro A, Cochran J, Brownawell B (2015) Geochronologies of

626 pharmaceuticals in a sewage-impacted estuarine urban setting (Jamaica Bay, New
 627 York). *Environ Sci Technol*. 49(10) 5948-5955 doi: 10.1021/es506009v

628 Li WC (2014) Occurrence, sources, and fate of pharmaceuticals in aquatic environment and
 629 soil. *Environ Poll* 187: 193–201. doi: 10.1016/j.envpol.2014.01.015

630 Ma R, Wang B, Yin L, Zhang Y, Deng S, Huang J, Wang Y, Yu G (2017) Characterization of
 631 pharmaceutically active compounds in Beijing, China: Occurrence pattern,
 632 spatiotemporal distribution and its environmental implication. *J Hazard Mat* 323: 147–
 633 155. doi: 10.1016/J.JHAZMAT.2016.05.030

634 Madureira TV, Barreiro JC, Rocha MJ, Rocha E, Cass QB, Tiritan ME (2010) Spatiotemporal
 635 distribution of pharmaceuticals in the Douro river estuary. *Sci Total Environ*
 636 408(22):5513-5520

637 Mavragani A, Sypsa K, Sampri A, Tsagarakis K (2016) Quantifying the UK Online Interest in
 638 Substances of the EU Watchlist for Water Monitoring: Diclofenac, Estradiol, and the
 639 Macrolide Antibiotics. *Water* 8: 542. doi: 10.3390/w8110542

640 Metcalfe CD, Chu S, Judt C, Li H, Oakes KD, Servos MR, Andrews DM (2010)
 641 Antidepressants and their metabolites in municipal wastewater, and downstream
 642 exposure in an urban watershed. *Environ Toxicol Chem* 29: 79–89. doi: 10.1002/etc.27

643 Mijangos L, Ziarrusta H, Ros O, Kortazar L, Fernández LA, Olivares M, Zuloaga O, Prieto A,
 644 Extebarria N (2018) Occurrence of emerging pollutants in estuaries of the Basque
 645 Country: analysis of sources and distribution, and assessment of the environmental
 646 risk. *Wat Res*. 147: 152-163 doi:10.1016/j.watres.2018.09.033

647 Minguez L, Pedelucq J, Farcy E, Ballandonne C, Budzinski H, Halm-Lemeille M-P (2016)
 648 Toxicities of 48 pharmaceuticals and their freshwater and marine environmental
 649 assessment in northwestern France. *Environ Sci Pollut Res Int* 23(6): 4992-5001 doi:
 650 10.1007/s11356-014-3662-5

651 Moreno-González R, Rodríguez-Mozaz S, Gros M, Pérez-Cánovas E, Barceló D, León VM
652 (2014) Input of pharmaceuticals through coastal surface watercourses into a
653 Mediterranean lagoon (Mar Menor, SE Spain): Sources and seasonal variations. *Sci*
654 *Total Environ* 490: 59–72. doi: 10.1016/j.scitotenv.2014.04.097

655 Munro K, Martina CPB, Loewenthal M, Comber S, Cowan DA, Pereira L, Barron LP (2019)
656 Evaluation of combined sewer overflow impacts on short-term pharmaceutical and illicit
657 drug occurrence in a heavily urbanised tidal river catchment (London, UK). *Sci Total*
658 *Environ* 657: 1099–1111 doi: 10.1016/j.scitotenv.2018.12.08

659 Nakada N, Hanamoto S, Jürgens MD, Johnson AC, Bowes MJ, Tanaka H (2017) Assessing
660 the population equivalent and performance of wastewater treatment through the ratios
661 of pharmaceuticals and personal care products present in a river basin: Application to
662 the River Thames basin, UK. *Sci Total Environ* 575: 1100–1108. doi:
663 10.1016/J.scitotenv.2016.09.180

664 National Health Service (2017) Prescriptions Dispensed in the Community - Statistics for
665 England, 2006-2016. Available from: [https://digital.nhs.uk/data-and-](https://digital.nhs.uk/data-and-information/publications/statistical/prescriptions-dispensed-in-the-community/prescriptions-dispensed-in-the-community-statistics-for-england-2006-2016-pas)
666 [information/publications/statistical/prescriptions-dispensed-in-the-](https://digital.nhs.uk/data-and-information/publications/statistical/prescriptions-dispensed-in-the-community/prescriptions-dispensed-in-the-community-statistics-for-england-2006-2016-pas)
667 [community/prescriptions-dispensed-in-the-community-statistics-for-england-2006-2016-](https://digital.nhs.uk/data-and-information/publications/statistical/prescriptions-dispensed-in-the-community/prescriptions-dispensed-in-the-community-statistics-for-england-2006-2016-pas)
668 [pas](https://digital.nhs.uk/data-and-information/publications/statistical/prescriptions-dispensed-in-the-community/prescriptions-dispensed-in-the-community-statistics-for-england-2006-2016-pas) (January 1, 2019).

669 National Health Service (2019) Prescriptions Dispensed in the Community - NHS Digital.
670 Available from: [https://digital.nhs.uk/data-and-](https://digital.nhs.uk/data-and-information/publications/statistical/prescriptions-dispensed-in-the-community)
671 [information/publications/statistical/prescriptions-dispensed-in-the-community](https://digital.nhs.uk/data-and-information/publications/statistical/prescriptions-dispensed-in-the-community) (January
672 8, 2019).

673 Ort C, Lawrence MG, Reungoat J, Mueller JF (2010) Sampling for PPCPs in Wastewater
674 Systems: Comparison of Different Sampling Modes and Optimization Strategies.
675 *Environ Sci Technol* 44: 6289–6296 doi: 10.1021/es100778d

676 Paíga P, Santos LHMLM, Ramos S, Jorge S, Silva JG, Delerue-Matos C (2016) Presence of

677 pharmaceuticals in the Lis river (Portugal): Sources, fate and seasonal variation. *Sci*
678 *Total Environ* 573: 164–177. doi: 10.1016/J.SCITOTENV.2016.08.089

679 Pohlert T (2014) The pairwise multiple comparison of mean ranks package (PMCMR).
680 Available from: <https://cran.r-project.org/package=PMCMR> (October 12, 2018).

681 Radjenovic J, Petrovic M, Barceló D (2007) Analysis of pharmaceuticals in wastewater and
682 removal using a membrane bioreactor. *Anal Bioanal Chem* 387: 1365–1377. doi:
683 10.1007/s00216-006-0883-6

684 Redshaw CH, Stahl-Timmins WM, Fleming LE, Davidson I, Depledge MH (2013) Potential
685 Changes in Disease Patterns and Pharmaceutical Use in Response to Climate Change.
686 *J Toxicol Environ Health B* 16: 285–320. doi: 10.1080/10937404.2013.802265

687 Reis-Santos P, Pais M, Duarte B, Cacador I, Freitas, A, Pouca ASV, Barbosa J, Leston S,
688 Rosa J, Ramos F, Cabral HN, Gillanders BM, Fronseca VF (2018) Screening of human
689 and veterinary pharmaceuticals in estuarine waters: A baseline assessment for the Tejo
690 estuary. *Mar Poll Bull* 135: 1079-1084. doi:10.1016/j.marpollbul.2018.08.036

691 Ridgway J, Shimmield G (2002) Estuaries as Repositories of Historical Contamination and
692 their Impact on Shelf Seas. *Estuar Coast Shelf Sci* 55: 903–928. doi:
693 10.1006/ECSS.2002.1035

694 Roberts PH, Thomas K V. (2006) The occurrence of selected pharmaceuticals in wastewater
695 effluent and surface waters of the lower Tyne catchment. *Sci Total Environ* 356: 143–
696 153. doi: 10.1016/j.scitotenv.2005.04.031

697 Roos V, Gunnarsson L, Fick J, Larsson DGJ, Rudén C (2012) Prioritising pharmaceuticals
698 for environmental risk assessment: Towards adequate and feasible first-tier selection.
699 *Sci Total Environ* 421 (102-110) doi: 10.1016/j.scitotenv.2012.01.039.

700 Santos LHMLM, Araújo AN, Fachini A, Matos-Delerue PC, Montenegro MCBSM (2010)
701 Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic

environment. *J Hazard Mat.* 175: 45-95 doi: 10.1016/j.jhazmat.2009.10.100

Styrishave B, Halling-Sørensen B, Ingerslev F (2011) Environmental risk assessment of three selective serotonin reuptake inhibitors in the aquatic environment: a case study including cocktail scenario. *Environ Toxicol Chem* 30: 254–261. Available from: 10.1002/etc.372.

Sun Q, Li Y, Li M, Ashfaq M, Lv M, Wang H, Hu A, Yu C (2016) PPCPs in Jiulong river estuary (China): spatiotemporal distributions, fate and their use as chemical markers of wastewater. *Chemosphere* 150: 596-604. doi:10/1016/j.chemosphere.2016.02.036

Tamtam F, Mercier F, Le Bot B, Eurin J, Tuc Dinh Q, Clement M, Chevreuil M (2008) Occurrence and fate of antibiotics in the Seine River in various hydrological conditions. *Sci Total Environ* 393 (1): 84–95. doi:10.1016/j.scitotenv.2007.12.009

Thomas K V, Hilton MJ (2004) The occurrence of selected human pharmaceutical compounds in UK estuaries. *Mar Poll Bull* 49: 436–444. doi: 10.1016/j.marpolbul.2004.02.028

Verlicchi P, Zambello E (2016) Predicted and measured concentrations of pharmaceuticals in hospital effluents. Examination of the strengths and weaknesses of the two approaches through the analysis of a case study. *Sci Total Environ* 565: 82–94. doi: 10.1016/j.scitotenv.2016.04.165

Vestel J, Caldwell DJ, Constantine L, D'Aco VJ, Davidson T, Dolan DG, Millard SP, Murray-Smith R, Parke NJ, Ryan JJ, Straub JO, Wilson P (2016) Use of acute and chronic ecotoxicity data in environmental risk assessment of pharmaceuticals. *Environ Toxicol Chem* 35: 1201–1212. doi: 10.1002/etc.3260

Vieno NM, Tuhkanen T, Kronberg L (2005) Seasonal Variation in the Occurrence of Pharmaceuticals in Effluents from a Sewage Treatment Plant and in the Recipient Water. *Environ Sci Technol* 39: 8220–8226. doi: 10.1021/es051124k

727 Weigel S, Kuhlmann J, Hühnerfuss H (2002) Drugs and personal care products as
 728 ubiquitous pollutants: occurrence and distribution of clofibric acid, caffeine and DEET in
 729 the North Sea. *Sci Total Environ* 295(1-3): 131-141. doi:10.1016/S0048=9697(02)0064-
 730 5

731 Wickham H (2016) ggplot2; Elegant Graphics for Data Analysis. Available from:
 732 <http://ggplot2.org>.

733 Wilkinson JL, Hooda PS, Swinden J, Barker J, Barton S (2017) Spatial distribution of organic
 734 contaminants in three rivers of Southern England bound to suspended particulate
 735 material and dissolved in water. *Sci Total Environ* 593–594: 487–497. doi:
 736 10.1016/J.SCITOTENV.2017.03.167

737 Xu W, Zhang G, Zhou S, Li X, Liu Y (2007) Determination of selected antibiotics in the
 738 Victoria Harbour and the Pearl River, South China using high-performance liquid
 739 chromatography-electrospray ionization tandem mass spectrometry. *Environ. Poll.* 145:
 740 672-679 doi: 10.1016/j.envpol.2006.05.038

741 Yang Y, Fu J, Peng H, Hou L, Liu M, Zhou JL (2011) Occurrence and phase distribution of
 742 selected pharmaceuticals in the Yangtze estuary and its coastal zone. *J Hazard Mat*
 743 190(1-3): 588-596 doi;10.1016/j.hazmat.2011.03.092

744 Yang Y, Cheng Q, Lin L, Wang X, Chen B, Luan T, Tam N (2016) Partitions and vertical
 745 profiles of 9 endocrine disrupting chemicals in an estuarine environment: Effect of tide,
 746 particle size and salinity. *Environ Poll.* 211: 58-66 doi: 10.1016/j.watres.2016.05.048

747 Zhang R, Zhang G, Zheng Q, Tang J, Chen Y, Xu W, Zou Y, Chen X (2012) Occurrence and
 748 risks of antibiotis in the Laizhou Bay, China: impacts of river discharge. *Ecotox Environ*
 749 *Safe* 80: 208-215 doi:10.1016/j.ecoenv.2012.03.002

750 Zhao H, Zhou JL, Zhang J (2015) Tidal impact on the dynamic behaviour of dissolved
 751 pharmaceuticals in the Yangtze estuary, China. *Sci Total Environ.* 536: 946-954

752 doi:10.1016/j.scitotenv.2015.06.055

753